Elevated high-sensitivity C-reactive protein/albumin ratio (CAR) was associated with angiographic no-reflow in NSTEMI patients undergoing PCI (median CAR 0.27 vs. 0.13).
Observational (n=400)
Does the high-sensitivity C-reactive protein/albumin ratio (CAR) predict angiographic no-reflow in NSTEMI patients undergoing PCI?
Elevated high-sensitivity C-reactive protein/albumin ratio is associated with angiographic no-reflow in NSTEMI patients undergoing PCI.
Absolute Event Rate: 0.27% vs 0.13%
Objective: This study examined the predictive value of the high-sensitivity C-reactive protein/albumin ratio (CAR) for angiographic no-reflow in NSTEMI patients undergoing PCI.Methods: We retrospectively evaluated 400 NSTEMI patients treated with PCI between 2021 and 2023. Patients were classified by post-procedural TIMI flow: no-reflow (TIMI ≤2) or normal reflow (TIMI 3). Clinical, laboratory, and angiographic variables were compared. Logistic regression identified independent predictors, and ROC analysis assessed CAR’s discriminative ability.Results: No-reflow occurred in 45 patients (11.3%). Compared with normal reflow, the no-reflow group had higher hs-CRP, lower albumin, and thus elevated CAR (median 0.27 vs. 0.13, p
Çelik et al. (2026) conducted an observational in NSTEMI (n=400). High-sensitivity C-reactive protein/albumin ratio (CAR) was evaluated on Angiographic no-reflow (TIMI ≤2). Elevated high-sensitivity C-reactive protein/albumin ratio (CAR) was associated with angiographic no-reflow in NSTEMI patients undergoing PCI (median CAR 0.27 vs. 0.13).